Article
The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.
The Journal of rheumatology - 1 Nov 1999
Choy E H, Rankin E C, Kassimos D, Vetterlein O, Garyfallos A, Ravirajan C T, Sopwith M, Eastell R, Kingsley G H, Isenberg D A, Panayi G S
Abstract excerpt
OBJECTIVE: We investigated the effect of an engineered human anti-tumor necrosis factor-alpha antibody, CDP571, on immune functions as well as bone and cartilage turnover in patients with rheumatoid arthritis (RA) in a placebo controlled trial. We also assessed the effects of repeated treatment with CDP571 in an open label continuation study. METHOD: Thirty-six patients were treated with either placebo or 0.1, 1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.